Rivoglitazone

Rivoglitazone
	File:Rivoglitazone.svg
Gene therapy
Clinical data
Physiological data
Legal status
Pharmacokinetic data
Identifiers
	IUPAC name 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione;
CAS Number	185428-18-6;
PubChem Template:Abbreviation	3055168;
Chemical and physical data
Formula	C20H19N3O4S
Molar mass	397.448 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4;

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.^[1]

It is being developed by Daiichi Sankyo Co.

References

↑ Schimke K, Davis TM (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185.